Patel, H, et al.
Systematic review of the incidence and prevalence of genital warts. BioMed Central Infectious Diseases
2012; 13: 39–39.
Winer, RL. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. American Journal of Epidemiology
2003; 157: 218–226.
Castle, PE, Maza, M. Prophylactic HPV vaccination: past, present, and future. Epidemiology and Infection
2016; 144: 449–468.
Insinga, RP, Dasbach, EJ, Myers, ER. The health and economic burden of genital warts in a set of private health plans in the United States. Clinical Infectious Diseases
2003; 36: 1397–1403.
Capra, G, et al.
Analysis of persistence of human papillomavirus infection in men evaluated by sampling multiple genital sites. European Review for Medical and Pharmacological Sciences
2015; 19: 4153–4163.
Pellati, D, et al.
Genital tract infections and infertility. European Journal of Obstetrics & Gynecology and Reproductive Biology
2008; 140: 3–11.
Patel, RV, Yanofsky, VR, Goldenberg, G. Genital warts: a comprehensive review. Journal of Clinical and Aesthetic Dermatology
2012; 5: 25–36.
Markowitz, LE, et al.
Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR: Recommendations and Reports
2014; 63: 1–30.
Satterwhite, CL, et al.
Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008. Sexually Transmitted Diseases
2013; 40: 187–193.
Shin, H-R, et al.
Prevalence and determinants of genital infection with papillomavirus, in female and male university students in Busan, South Korea. Journal of Infectious Diseases
2004; 190: 468–476.
Park, SJ, et al.
Prevalence and determinants of high-risk human papillomavirus infection in male genital warts. Korean Journal of Urology
2014; 55: 207–212.
Centers for Disease Control Prevention. Recommendations on the use of quadrivalent human papillomavirus vaccine in males – advisory committee on immunization practices (ACIP), 2011. MMWR Morbidity and Mortality Weekly Report
2011; 60: 1705.
Kim, MK, No, JH, Song, YS. Human papillomavirus vaccine. Journal of the Korean Medical Association
2009; 52: 1180–1186.
Anon. Human papillomavirus vaccines. WHO position paper. Weekly Epidemiological Record
2009; 84: 118–131.
Anon. Human papillomavirus vaccines: WHO position paper, October 2014-recommendations. Vaccine
2015; 33: 4383–4384.
Capra, G, et al.
Potential impact of a nonavalent HPV vaccine on HPV related low-and high-grade cervical intraepithelial lesions: a referral hospital-based study in Sicily. Human Vaccines & Immunotherapeutics
2017; 13: 1839–1843.
Li, N, et al.
Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. International Journal of Cancer
2011; 128: 927–935.
Ali, H, et al.
Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. British Medical Journal
2013; 346: f2032.
Hartwig, S, et al.
Estimation of the epidemiological burden of human papillomavirus-related cancers and non-malignant diseases in men in Europe: a review. BMC Cancer
2012; 12: 30.
Read, TR, et al.
The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sexually Transmitted Infections
2011; 87: 544–547.
World Health Organization. International Statistical Classification of Diseases and Related Health Problems. 10th edn.
Geneva, CH: World Health Organization, 1989.
Jung, YH, Ko, S. The socioeconomic cost of diseases in Korea. Journal of Preventive Medicine and Public Health Yebang Uihakhoe Chi
2006; 39: 499–504.
Park, CS, et al.
Cost-of-illness study of asthma in Korea: estimated from the Korea National Health insurance claims database. Journal of Preventive Medicine and Public Health Yebang Uihakhoe Chi
2006; 39: 397–403.
National Health Insurance Corporation. Survey of Medical Charges Paid by Patients with Health Insurance in 2010. Seoul: National Health Insurance Corporation, 2010.
Drummond, MF, et al.
Methods for the Economic Evaluation of Health Care Programmes. 3rd edn.
Oxford, UK: Oxford University Press, 2005.
No, IC, Suh, MH, Kim, YL. Socioeconomic Costs of Alcohol and Policy Issues. Seoul: Korea Institute of Health and Social Affairs, 1997.
Future I/II Study Group, et al.
Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ: British Medical Journal
2010; 341: c3493.
Garland, SM, et al.
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. New England Journal of Medicine
2007; 356: 1928–1943.
Drolet, M, et al.
Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infectious Diseases
2015; 15: 565–580.
Giuliano, AR, et al.
Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. New England Journal of Medicine
2011; 364: 401–411.
Markowitz, LE, et al.
Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. Journal of Infectious Diseases
2013; 208: 385–393.
Kann, L, et al.
Youth risk behavior surveillance – United States, 2015. MMWR Surveillance Summaries
2016; 65: 1–174.